Dr. Martens plc (LON:DOCS – Get Free Report) insider Giles Wilson acquired 237 shares of the firm’s stock in a transaction dated Wednesday, November 11th. The stock was purchased at an average cost of GBX 63 per share, with a total value of £149.31.
Dr. Martens Stock Down 18.3%
Dr. Martens stock opened at GBX 53.10 on Thursday. The company has a debt-to-equity ratio of 108.85, a current ratio of 2.61 and a quick ratio of 1.13. The company’s 50-day moving average is GBX 67.13 and its 200-day moving average is GBX 69.53. The firm has a market capitalization of £508.31 million, a PE ratio of 22.12, a P/E/G ratio of 6.40 and a beta of 0.26. Dr. Martens plc has a fifty-two week low of GBX 52.10 and a fifty-two week high of GBX 90.
Dr. Martens (LON:DOCS – Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported GBX (1) earnings per share (EPS) for the quarter. Dr. Martens had a net margin of 3.11% and a return on equity of 6.89%. The firm had revenue of £290.40 million during the quarter. Sell-side analysts anticipate that Dr. Martens plc will post 2.58 earnings per share for the current year.
Wall Street Analyst Weigh In
Separately, Berenberg Bank restated a “buy” rating and issued a GBX 110 price objective on shares of Dr. Martens in a research note on Friday, October 9th. Two research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 105.
View Our Latest Stock Analysis on Dr. Martens
About Dr. Martens
Dr. Martens is an iconic British footwear brand founded in Northamptonshire, England. Its first silhouette, the 1460 boot – named after the date it was produced – rolled off the production line on 1st April 1960. Originally chosen by workers for their air-cushioned comfort and durability, “Docs” or “DM’s” were later adopted by musicians and subcultural pioneers who took them from the street to the global stage. Over six decades later, Dr. Martens operates in more than 60 countries and employs around 3,600 people.
See Also
- Five stocks we like better than Dr. Martens
- The Post-Midterm Rally Clock Is Ticking—and These 3 AI Stocks Stand Out
- Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
- Palantir’s Real Washington Risk Isn’t the Budget—It’s Oversight
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.
